Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice

Karen Wagner, Jennifer Gilda, Jun Yang, Debin Wan, Christophe Morisseau, Aldrin V Gomes, Bruce D. Hammock

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The soluble epoxide hydrolase (sEH) is a regulatory enzyme responsible for the metabolism of bioactive lipid epoxides of both omega-6 and omega-3 long chain polyunsaturated fatty acids. These natural epoxides mediate cell signaling in several physiological functions including blocking inflammation, high blood pressure and both inflammatory and neuropathic pain. Inhibition of the sEH maintains the level of endogenous bioactive epoxy-fatty acids (EpFA) and allows them to exert their generally beneficial effects. The Akita (Ins2Akita or Ins2C96Y) mice represent a maturity-onset of diabetes of the young (MODY) model in lean, functionally unimpaired animals, with a sexually dimorphic disease phenotype. This allowed for a test of male and female mice in a battery of functional and nociceptive assays to probe the role of sEH in this system. The results demonstrate that inhibiting the sEH is analgesic in diabetic neuropathy and this occurs in a sexually dimorphic manner. Interestingly, sEH activity is also sexually dimorphic in the Akita model, and moreover correlates with disease status particularly in the hearts of male mice. In addition, in vivo levels of oxidized lipid metabolites also correlate with increased sEH expression and the pathogenesis of disease in this model. Thus, sEH is a target to effectively block diabetic neuropathic pain but also demonstrates a potential role in mitigating the progression of this disease.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalBehavioural Brain Research
Volume326
DOIs
StatePublished - May 30 2017

Fingerprint

Epoxide Hydrolases
Epoxy Compounds
Neuralgia
Diabetic Neuropathies
Unsaturated Fatty Acids
Lipid Metabolism
Analgesics
Disease Progression
Fatty Acids
Hypertension
Inflammation
Phenotype
Lipids
Enzymes

Keywords

  • Anti-nociception
  • Chronic pain
  • Diabetic neuropathy
  • Epoxy-fatty acid (EpFA)
  • Soluble epoxide hydrolase (sEH)

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Wagner, K., Gilda, J., Yang, J., Wan, D., Morisseau, C., Gomes, A. V., & Hammock, B. D. (2017). Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice. Behavioural Brain Research, 326, 69-76. https://doi.org/10.1016/j.bbr.2017.02.048

Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice. / Wagner, Karen; Gilda, Jennifer; Yang, Jun; Wan, Debin; Morisseau, Christophe; Gomes, Aldrin V; Hammock, Bruce D.

In: Behavioural Brain Research, Vol. 326, 30.05.2017, p. 69-76.

Research output: Contribution to journalArticle

Wagner, K, Gilda, J, Yang, J, Wan, D, Morisseau, C, Gomes, AV & Hammock, BD 2017, 'Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice', Behavioural Brain Research, vol. 326, pp. 69-76. https://doi.org/10.1016/j.bbr.2017.02.048
Wagner, Karen ; Gilda, Jennifer ; Yang, Jun ; Wan, Debin ; Morisseau, Christophe ; Gomes, Aldrin V ; Hammock, Bruce D. / Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice. In: Behavioural Brain Research. 2017 ; Vol. 326. pp. 69-76.
@article{a69c739d689f4676b1c4bab91daf8692,
title = "Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice",
abstract = "The soluble epoxide hydrolase (sEH) is a regulatory enzyme responsible for the metabolism of bioactive lipid epoxides of both omega-6 and omega-3 long chain polyunsaturated fatty acids. These natural epoxides mediate cell signaling in several physiological functions including blocking inflammation, high blood pressure and both inflammatory and neuropathic pain. Inhibition of the sEH maintains the level of endogenous bioactive epoxy-fatty acids (EpFA) and allows them to exert their generally beneficial effects. The Akita (Ins2Akita or Ins2C96Y) mice represent a maturity-onset of diabetes of the young (MODY) model in lean, functionally unimpaired animals, with a sexually dimorphic disease phenotype. This allowed for a test of male and female mice in a battery of functional and nociceptive assays to probe the role of sEH in this system. The results demonstrate that inhibiting the sEH is analgesic in diabetic neuropathy and this occurs in a sexually dimorphic manner. Interestingly, sEH activity is also sexually dimorphic in the Akita model, and moreover correlates with disease status particularly in the hearts of male mice. In addition, in vivo levels of oxidized lipid metabolites also correlate with increased sEH expression and the pathogenesis of disease in this model. Thus, sEH is a target to effectively block diabetic neuropathic pain but also demonstrates a potential role in mitigating the progression of this disease.",
keywords = "Anti-nociception, Chronic pain, Diabetic neuropathy, Epoxy-fatty acid (EpFA), Soluble epoxide hydrolase (sEH)",
author = "Karen Wagner and Jennifer Gilda and Jun Yang and Debin Wan and Christophe Morisseau and Gomes, {Aldrin V} and Hammock, {Bruce D.}",
year = "2017",
month = "5",
day = "30",
doi = "10.1016/j.bbr.2017.02.048",
language = "English (US)",
volume = "326",
pages = "69--76",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibition alleviates neuropathy in Akita (Ins2 Akita) mice

AU - Wagner, Karen

AU - Gilda, Jennifer

AU - Yang, Jun

AU - Wan, Debin

AU - Morisseau, Christophe

AU - Gomes, Aldrin V

AU - Hammock, Bruce D.

PY - 2017/5/30

Y1 - 2017/5/30

N2 - The soluble epoxide hydrolase (sEH) is a regulatory enzyme responsible for the metabolism of bioactive lipid epoxides of both omega-6 and omega-3 long chain polyunsaturated fatty acids. These natural epoxides mediate cell signaling in several physiological functions including blocking inflammation, high blood pressure and both inflammatory and neuropathic pain. Inhibition of the sEH maintains the level of endogenous bioactive epoxy-fatty acids (EpFA) and allows them to exert their generally beneficial effects. The Akita (Ins2Akita or Ins2C96Y) mice represent a maturity-onset of diabetes of the young (MODY) model in lean, functionally unimpaired animals, with a sexually dimorphic disease phenotype. This allowed for a test of male and female mice in a battery of functional and nociceptive assays to probe the role of sEH in this system. The results demonstrate that inhibiting the sEH is analgesic in diabetic neuropathy and this occurs in a sexually dimorphic manner. Interestingly, sEH activity is also sexually dimorphic in the Akita model, and moreover correlates with disease status particularly in the hearts of male mice. In addition, in vivo levels of oxidized lipid metabolites also correlate with increased sEH expression and the pathogenesis of disease in this model. Thus, sEH is a target to effectively block diabetic neuropathic pain but also demonstrates a potential role in mitigating the progression of this disease.

AB - The soluble epoxide hydrolase (sEH) is a regulatory enzyme responsible for the metabolism of bioactive lipid epoxides of both omega-6 and omega-3 long chain polyunsaturated fatty acids. These natural epoxides mediate cell signaling in several physiological functions including blocking inflammation, high blood pressure and both inflammatory and neuropathic pain. Inhibition of the sEH maintains the level of endogenous bioactive epoxy-fatty acids (EpFA) and allows them to exert their generally beneficial effects. The Akita (Ins2Akita or Ins2C96Y) mice represent a maturity-onset of diabetes of the young (MODY) model in lean, functionally unimpaired animals, with a sexually dimorphic disease phenotype. This allowed for a test of male and female mice in a battery of functional and nociceptive assays to probe the role of sEH in this system. The results demonstrate that inhibiting the sEH is analgesic in diabetic neuropathy and this occurs in a sexually dimorphic manner. Interestingly, sEH activity is also sexually dimorphic in the Akita model, and moreover correlates with disease status particularly in the hearts of male mice. In addition, in vivo levels of oxidized lipid metabolites also correlate with increased sEH expression and the pathogenesis of disease in this model. Thus, sEH is a target to effectively block diabetic neuropathic pain but also demonstrates a potential role in mitigating the progression of this disease.

KW - Anti-nociception

KW - Chronic pain

KW - Diabetic neuropathy

KW - Epoxy-fatty acid (EpFA)

KW - Soluble epoxide hydrolase (sEH)

UR - http://www.scopus.com/inward/record.url?scp=85014820250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014820250&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2017.02.048

DO - 10.1016/j.bbr.2017.02.048

M3 - Article

C2 - 28259677

AN - SCOPUS:85014820250

VL - 326

SP - 69

EP - 76

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -